GPC1 and pancreatic intraductal papillary-mucinous neoplasm: Melo et al. found that crExos GPC1+ levels were consistently higher in patients with intraductal papillary mucinous neoplasms (IPMN), compared to healthy controls, or patients with CP or SCA [12].